Onconova Therapeutics Inc (ONTX)

[Wildbilly]

ONTX: Key catalysts coming up starting June 5

Time and Location: 8:00 AM — 11:30 AM, McCormick Place, Hall A
Presenter: Aref Al-Kali, MD, Mayo Clinic - Rochester, Minnesota

Onconova (ONTX) To Present A Poster Session Relating To Intravenous Rigosertib At The 2017 ASCO Annual Meeting

NEWTOWN, Pa., May 18, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced details relating to a poster presentation addressing Intravenous Rigosertib in Second-line Higher Risk MDS at the upcoming American Society of Clinical Oncology Annual Meeting taking place June 2nd-6th in Chicago.


Further Rationale for Rigosertib in a Second-line HR-MDS Setting
Abstract Number: 7056

Title: Relationship of Bone Marrow Blast (BMBL) response to Overall Survival (OS) in a Multicenter study of Rigosertib (Rigo) in Patients with Myelodysplastic Syndromes (MDS) with Excess Blasts Progressing on or After Treatment with a Hypomethylating Agent (HMA).
Date: Monday, June 5, 2017
http://www.biospace.com/news_story.aspx?StoryID=457128&full=1